San Francisco-based Alta Partners joins as lead investor
Amsterdam, The Netherlands, June 26, 2007 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces that it has completed a EUR 15 million private financing round. Alta Partners, a prominent life science venture capital company based in San Francisco, led the financing round. Other major new investors include Quest for Growth and MedSciences Capital. All of the major existing investors also contributed to this round, including founding investor Life Sciences Partners, Esprit Capital Partners LLP and N.V. NOM (Investment and Development Agency for the Northern Netherlands).
The Kiadis Pharma product pipeline is focused on providing novel treatments for significant unmet medical needs in the field of bone marrow transplants and the treatment of aggressive cancers. The four most advanced products are currently in clinical trials, ranging from Phase I to entering Phase III. Kiadis Pharma’s lead product is ATIR™, which enables the use of mismatched bone-marrow donors in transplantations for terminally ill blood cancer patients. Kiadis Pharma is a Dutch company with locations in The Netherlands and Canada.
Ekaterina Smirnyagina, of Alta Partners, joining the Supervisory Board of Kiadis Pharma, added: “We were impressed by the broad endorsement of Kiadis Pharma’s clinical programs within the international scientific community. Its lead product, ATIR™, is being tested by opinion leaders in the field as a potentially life-saving treatment option for patients unable to find a matched bone-marrow donor, while also preventing graft-versus-host disease (GvHD). We look forward to working with the seasoned management of Kiadis Pharma and its investors on building a premier oncology company.”
Mark Wegter, Chairman of the Supervisory Board of Kiadis Pharma and General Partner at LSP, commented: “Following the acquisition of Celmed late last year, this is yet again a key milestone that has been achieved by the company and its management. It marks the next step in the further growth of Kiadis Pharma which we feel is positioned to become a major force in the European biotech arena. We are very pleased to see our excitement about the company being shared by other high quality US and European investors.”
Manja Bouman, CEO of Kiadis Pharma, stated: “We are delighted by this latest funding round. Our shareholders provide a particularly strong knowledge base with an excellent track record in life sciences. Bringing in Alta Partners as our lead investor is an important external validation. Not only does it confirm the potential of many of our clinical trials, but it also demonstrates the overall confidence of sophisticated investors in our novel treatments.” She added: “Earlier this year we announced the trial of our ATIR™ product on nine end-stage blood cancer patients who were transplanted in the mismatched setting with the use of ATIR™. All patients responded well. This treatment is at a very exciting stage in its development and this trial was an important milestone in our revolutionary approach to providing successful mismatch transplants for end stage blood cancer patients.”
ATIR™ is a T cell based medicinal product enabling stem cell transplantations using partially mismatched (haploidentical) family members as donors for patients suffering from blood cancer who do not have a standard of care stem cell donor available. A hematopoietic stem cell transplantation (HSCT) is the only potentially curative option for many patients but a matching donor is available for only half of the patients in need. ATIR™ thus has the potential to address this unmet need and to make an HSCT available for all patients worldwide.
Those T cells in a haploidentical graft which would cause Graft-versus-Host-Disease (GvHD) are selectively eliminated using proprietary technology to produce ATIR™. ATIR™ is administered as an adjunctive treatment after a T cell depleted haploidentical HSCT facilitating early immune reconstitution without causing life threatening (acute) GvHD.
In a Phase I/II study in which high risk leukemia patients with very poor prognosis were treated with escalating doses of ATIR™ after a haploidentical HSCT, long term safety, efficacy and proof of concept were confirmed in terms of absence of Grade III/IV (life threatening) acute GvHD, reduced rates of infection, reduced Transplant Related Mortality and high Overall Survival. Positive follow up results from this study demonstrating 67% survival after five years and no Transplant Related Mortality in the nine patients who received an efficacious dose of ATIR™ were recently reported.
An international multi center Phase II study including patients with acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome, to corroborate and extend the safety and efficacy results from the Phase I/II study, is now ongoing with topline data expected in the first half of 2014.
ATIR™ has been granted Orphan Drug Designation both in the EU and the USA. Together, both regions represent a combined primary market potential of more than EUR 1 billion per year.
About Kiadis Pharma
Kiadis Pharma B.V. is a private, clinical stage biopharmaceutical company focused on the development of innovative and potentially life saving therapies for patients with late stage blood cancers and related disorders, an area of significant unmet medical need.
Kiadis Pharma’s lead product is ATIR™, a cell based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors. Kiadis Pharma is collaborating with internationally renowned centers in Europe and North America for the successful development and manufacturing of ATIR™. Kiadis Pharma recently obtained a GMP manufacturing license and GMP certificate for its Quality Control laboratory.
Kiadis Pharma is supported by a strong group of leading international investors including LSP, Alta Partners, DFJ Esprit, Quest for Growth, MedSciences Capital and NOM. Kiadis Pharma is based in Amsterdam, The Netherlands.